A 55-year-old man undergoing percutaneous coronary intervention receives abciximab. Its antiplatelet action is by:

• A Blocking ADP binding at the P2Y12 receptor
• B Binding the glycoprotein IIb/IIIa receptor and blocking fibrinogen cross-linking ✓
• C Inhibiting phosphodiesterase type 3
• D Irreversibly acetylating cyclooxygenase-1

Explanation

Abciximab is a monoclonal antibody Fab fragment directed against glycoprotein IIb/IIIa, the final common receptor through which fibrinogen bridges activated platelets. Blocking it prevents aggregation regardless of the upstream agonist. Eptifibatide and tirofiban act at the same receptor but are small molecules. P2Y12 blockade describes clopidogrel and ticagrelor, and PDE3 inhibition describes cilostazol and dipyridamole.

Reference: Katzung's Basic and Clinical Pharmacology, 16th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.